Patents Assigned to Schering AG
  • 16-Halogen-epothilone derivatives, method for producing them and their pharmaceutical use
    Patent number: 6610736
    Abstract: The invention relates to novel epothilone derivatives of general formula (I), wherein R8 means a halogen atom, especially a fluorine or chlorine atom, and the remaining substituents have the meanings given in the description. The novel compounds are suitable for producing medicaments.
    Type: Grant
    Filed: December 7, 2001
    Date of Patent: August 26, 2003
    Assignee: Schering AG
    Inventors: Ulrich Klar, Werner Skuballa, Bernd Buchmann, Wolfgang Schwede, Michael Schirner
  • Contraception method using competitive progesterone antagonists and novel compounds useful therein
    Patent number: 6608074
    Abstract: Competitive progesterone antagonists, including two novel steroids, viz., 11&bgr;,19-[4-(cyanophenyl)-o-phenylene]-17&bgr;-hydroxy-17&agr;-(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one and 11&bgr;,19-[4-(3-pyridinyl)-o-phenylene]-17&bgr;-hydroxy-17&agr;-(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one, inhibit formation of endometrial glands at below their ovulation inhibiting dose and the abortive dose, and thus achieve oral contraception in females without adversely affecting the menstrual cycle and without risk of aborting a previous implanted fertilized egg or a fetus.
    Type: Grant
    Filed: November 28, 2001
    Date of Patent: August 19, 2003
    Assignee: Schering AG
    Inventors: Krzystof Chwalisz, Walter Elger, Karin Schmidt-Gollwitzer, Eckhard Ottow
  • Method for producing epothilone B and derivatives, and intermediate products for this method
    Patent number: 6605726
    Abstract: The invention relates to a method for producing epothilone B and derivatives, and to intermediate products for this method. According to the novel method, the epothilone B or derivatives are produced in high yields from the C1-C6, C7-C10 and C11-C20-fragments 2, 3 and 4 that can be obtained economically and diastereomerically purely (the variable radicals having the meanings given in the description ).
    Type: Grant
    Filed: June 1, 2001
    Date of Patent: August 12, 2003
    Assignee: Schering AG
    Inventors: Johann Mulzer, Andreas Mantoulidis, Elisabeth Öhler
  • ARL-2 for birth control
    Publication number: 20030148337
    Abstract: A human ARL-2 protein as well as its use for fertility disorders, therapy and diagnosis are described.
    Type: Application
    Filed: October 21, 2002
    Publication date: August 7, 2003
    Applicant: Schering AG
    Inventors: Monika Lessl, Michaele Peter-Kottig
  • Protected 3,-5-dihydroxy-2,2-dimethyl-valeronitriles for the synthesis of epothilones and epothilone derivatives and process for the production
    Publication number: 20030149281
    Abstract: The invention relates to 3,5-dihydroxy-2,2-dimethyl-valeronitriles for the synthesis of epothilones and epothilone derivatives and process for the production of these new intermediate products in the synthesis and the use for the production of epothilones or epothilone derivatives.
    Type: Application
    Filed: August 5, 2002
    Publication date: August 7, 2003
    Applicant: Schering AG
    Inventors: Jurgen Westermann, Johannes Platzek, Orlin Petrov
  • Antigestagenically active steroids with a fluorinated 17-alpha-alkyl chain
    Publication number: 20030134834
    Abstract: This invention describes the new 17&agr;-fluoroalkyl steroids of general formula I 1
    Type: Application
    Filed: November 27, 2002
    Publication date: July 17, 2003
    Applicant: Schering AG
    Inventors: Wolfgang Schwede, Arwed Cleve, Ulrich Klar, Gunter Neef, Kristof Chwalisz, Martin Schneider, Ulrike Fuhrmann, Holger Heb-Stumpp
  • Therapeutic use of estrogen receptor (ER)beta-selective agonists for triggering somatotropic, organotropic and anticatabolic effects (somatotropic therapy)
    Publication number: 20030130249
    Abstract: This invention describes the use of estrogen receptor (ER)&bgr;-selective agonists for the production of a pharmaceutical agent for triggering somatotropic and/or organotropic effects in the CNS, the circulatory system, the skeletal system and/or the immune system in the aging male and female organism (anticatabolic therapy).
    Type: Application
    Filed: October 17, 2002
    Publication date: July 10, 2003
    Applicant: Schering AG
    Inventors: Walter Elger, Gudrun Reddersen, Birgitt Schneider, Alexander Hillisch, Olaf Peters, Dirk Kosemund, Gerd Muller
  • Human mater proteins
    Publication number: 20030125282
    Abstract: Two human MATER proteins as well as their use for fertility disorders, therapy and diagnosis are described.
    Type: Application
    Filed: August 12, 2002
    Publication date: July 3, 2003
    Applicant: Schering AG
    Inventors: Bertram Weiss, Monika Lessl, Michaele Peters-Kottig, Georg Beckmann
  • N-methyl-homocysteines and their use as well as process for their production
    Publication number: 20030120032
    Abstract: The synthesis of N-methyl-homocysteines and their use are described.
    Type: Application
    Filed: November 15, 2002
    Publication date: June 26, 2003
    Applicant: Schering AG
    Inventors: Marc Willuhn, Johannes Platzek, Eckhard Ottow, Orlin Petrov, Claudia Borm, Dirk Hinz, Gregor Mann, John Lister-James, David M. Wilson
  • Human interferon-beta formulations
    Publication number: 20030118548
    Abstract: The invention provides a stable pharmaceutical composition containing biologically active human interferon-&bgr; (IFN-&bgr;), preferably IFN &bgr;1b produced in a bacterial host, dissolved in an aqueous-based solution containing a glycine buffer at a pH of about 2.0 to about 4.0. The invention of also provides stable IFN-&bgr; lyophilizates prepared from biologically active IFN-&bgr;, dissolved in an aqueous-based solution containing a glycine buffer at a pH of about 2.0 to about 4.0.
    Type: Application
    Filed: July 9, 2002
    Publication date: June 26, 2003
    Applicant: Schering AG
    Inventors: Michael McCaman, Susanne Ottoboni, Erno Pungor
  • C13-substituted estra-1,3,5,(10)-trien-3-yl sulfamates, methods of preparing same, and pharmaceutical compositions containing these compounds
    Patent number: 6583130
    Abstract: The invention relates to new C13-substituted estra-1,3,5(10)-trien-3-yl sulfamates of general formula I, wherein R1 represents an acyl residue, oxycarbonyl residue, aminocarbonyl residue, sulfonyl residue, or aminosulfonyl residue, and R15 represents ethyl, methods of preparing same, and pharmaceutical compositions containing these compounds. The compounds of the invention of general formula I inhibit the activity of steroid sulfatase (EC 3.1.6.2) and do not exhibit any estrogenic effect.
    Type: Grant
    Filed: September 6, 2000
    Date of Patent: June 24, 2003
    Assignee: Schering AG
    Inventors: Sigfrid Schwarz, Gerd Müller, Dirk Kosemund, Margit Richter, Olaf Peters, Ina Scherlitz-Hofmann, Thomas Michel, Walter Elger, Gudrun Reddersen, Birgitt Schneider
  • Device and process for separating magnetic materials from pharmaceutical preparations, their starting or intermediate products, as well as agents that are produced with the aid of said device
    Publication number: 20030108613
    Abstract: The invention relates to a device for magnetic separation of pharmaceutical preparations, their starting or intermediate products that contain a separation space, in which a magnetic gradient field prevails and which has an inlet and an outlet, whereby the device is embodied in the form of an attachment filter for injection instruments or infusion instruments.
    Type: Application
    Filed: December 19, 2002
    Publication date: June 12, 2003
    Applicant: Schering AG
    Inventors: Werner Weitschies, Thomas Rheinlander, Wolfgang Ebert, Bernard Better
  • Macrocyclic metal complexes and their use for the production of conjugates with biomolecules
    Publication number: 20030108486
    Abstract: The invention relates to macrocyclic metal complexes and their production and use for the production of conjugates with biomolecules. The conjugates are suitable as contrast media in NMR diagnosis and radiodiagnosis as well as for radiotherapy. High relaxivity is achieved by a special liganding of macrocyclic compounds, and a fine-tuning of the relaxivity is made possible.
    Type: Application
    Filed: July 19, 2002
    Publication date: June 12, 2003
    Applicant: Schering AG
    Inventors: Johannes Platzek, Heribert Schmitt-Willich, Gunther Michl, Thomas Frenzel, Detlev Sulzle, Hans Bauer, Bernd Raduchel, Hanns-Joachim Weinmann, Heiko Schirmer
  • Methods for treating HIV-Infected Patients by the Administration of GM-CSF and a protease inhibitor
    Patent number: 6576231
    Abstract: Provided are methods for inducing an increase in the number of CD4+ T-lymphocytes in HIV-infected patients by administering human GM-CSF. The GM-CSF may be administered concurrently with at least one antiretroviral agent.
    Type: Grant
    Filed: September 12, 1997
    Date of Patent: June 10, 2003
    Assignee: Schering AG
    Inventor: Roger M. Echols
  • Quinoline, isoquinoline and phthalazine derivatives as antagonists of the gonadotropin-releasing hormone
    Publication number: 20030105328
    Abstract: The invention relates to new quinoline, isoquinoline and phthalazine derivatives as antagonists of the gonadotropin-releasing hormone.
    Type: Application
    Filed: February 21, 2002
    Publication date: June 5, 2003
    Applicant: Schering AG
    Inventors: Peter Strehlke, Peter Droescher, Ulrich Buehmann, Norbert Schmees, Peter Muhn, Holger Hess-Stumpp, Ronald Kuhne, Eckhard Guenther, Emmanual Polymeropoulos, Antonius Ter Laak
  • Antitumor wirksame 2-alkoxyestradiolsulfamate
    Publication number: 20030100544
    Abstract: The present invention relates to the use of 2-alkoxyestrogen sulfamates of general formula I 1
    Type: Application
    Filed: August 13, 2002
    Publication date: May 29, 2003
    Applicant: Schering AG
    Inventors: Ina Scherlitz-Hofmann, Jens Hoffmann, Alexander Hillisch, Eberhard Unger, Tobias Neumann, Sigfrid Schwarz, Olaf Peters, Thomas Michel
  • Solid pharmaceutical agent formulation for a piperazine urea derivative
    Publication number: 20030087913
    Abstract: A solid pharmaceutical agent formulation that contains (2R)-1-((4-chloro-2-(ureido)phenoxy)methyl)carbonyl-2-methyl-4-(4-fluorobenzyl)piperazine or a salt thereof is described.
    Type: Application
    Filed: October 18, 2002
    Publication date: May 8, 2003
    Applicant: Schering AG
    Inventors: Heiko Kranz, Christoph Volkel, Ralph Lipp, Johannes Tack, Herbert Wiesinger
  • Process for the production of peracylated 1-0-glycosides
    Publication number: 20030069402
    Abstract: The invention relates to a process for the production of peracylated 1-O-glycosides of general formula I or salts thereof 1
    Type: Application
    Filed: July 11, 2002
    Publication date: April 10, 2003
    Applicant: Schering AG
    Inventors: Johannes Platzek, Klaus-Dieter Graske, Ulrich Niedballa
  • Lipophilic metal complexes for necrosis and infarction imaging
    Publication number: 20030064026
    Abstract: This invention describes the use of metal complexes that have a plasma protein bond of at least 10% as imaging diagnostic agents for locating an infarction or a necrosis using lasting positive visualization.
    Type: Application
    Filed: October 7, 2002
    Publication date: April 3, 2003
    Applicant: Schering AG
    Inventors: Johannes Platzek, Ulrich Speck, Ulrich Niedballa, Bernd Raduchel, Hanns Weinmann, Wolfgang Ebert
  • 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutial agents as well as pharmaceutical preparations that contain these derivatives
    Publication number: 20030055057
    Abstract: The invention relates to novel benzimidazole derivatives with general formula I, whereby radicals R1, R2, R3, A, B and Y have the meanings that are indicated in the description and the claims, the use of these compounds for the production of a pharmaceutical agent for treating and for preventing diseases that are associated with microglia activation, as well as pharmaceutical preparations that contain these compounds.
    Type: Application
    Filed: July 5, 2002
    Publication date: March 20, 2003
    Applicant: Schering AG
    Inventors: Thorsten Blume, Wolfgang Halfbrodt, Joachim Kuhnke, Ursula Moenning, Herbert Schneider, Bernd Elger